Patent System Debate Continues

Brazil's patent system for pharmaceutical products remains concerning for many multinational pharmaceutical companies. One of the major causes of unease is the role of the National Health Surveillance Agency (ANVISA) in determining the validity of patents for drugs, an issue highlighted by the United States Trade Representative (USTR). ANVISA's role and relationship with intellectual property (IP) bodies was a key theme in the quarterly ANIVSA debate, held on November 10

To read the full article, please sign in or take a free trial.